4.5 Review

Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspective

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Pharmacology & Pharmacy

Annotated guidance to the European Medicines Agency (EMA) guidelines and regulatory documents. A new series of the BJCP

Adam Cohen et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)

Review Endocrinology & Metabolism

Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned

Matthew T. Drake et al.

ENDOCRINE REVIEWS (2017)

Article Medicine, General & Internal

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial

Paul D. Miller et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Article Medicine, General & Internal

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

F. Cosman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Endocrinology & Metabolism

Clinician's Guide to Prevention and Treatment of Osteoporosis

F. Cosman et al.

OSTEOPOROSIS INTERNATIONAL (2014)

Article Medicine, General & Internal

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Article Endocrinology & Metabolism

The food and drug administration's osteoporosis guidance document: Past, present, and future

EG Colman

JOURNAL OF BONE AND MINERAL RESEARCH (2003)

Article Medicine, General & Internal

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

RM Neer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)